Internal Reference Number: FOI_7860
Date Request Received: 03/04/2024 00:00:00
Date Request Replied To: 08/05/2024 00:00:00
This response was sent via: By Email
Request Summary: Treatment of dermatological conditions
Request Category: Companies
| Question Number 1: How many patients were treated in the last 4 months (December 2023 to March 2024) by the dermatology department with each of the following products: Abrocitinib Acitretin Alitretinoin Azathioprine Baricitinib Ciclosporin Dupilumab Lebrikizumab Methotrexate Mycophenolate mofetil Pimecrolimus Phototherapy (UVB or PUVA) - for Atopic Dermatitis only Tacrolimus ointment Tralokinumab Upadacitinib | |
| Answer To Question 1: Abrocitinib <5 Acitretin 9 Alitretinoin 26 Azathioprine <5 Baricitinib 0 Ciclosporin <5 Dupilumab 22 Lebrikizumab 0 Methotrexate (oral and subcutaneous) 35 Mycophenolate <5 Pimecrolimus 5 Phototherapy (UVB or PUVA) - 19 Tacrolimus 26 Tralokinumab 9 Upadacitinib <5 | |
| Question Number 2: Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: Age 6-11 Age 12-17 Age 18 and above | |
| Answer To Question 2: 6 to 11years = 8 patients 12 to 17years= 9 patients 18 and over = 144 patients | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
